Trial Profile
A Randomized, Double-blind, Placebo-Controlled, Four- Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-5788 in Healthy Adult Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs ONO-5788 (Primary) ; Octreotide
- Indications Acromegaly
- Focus Adverse reactions; First in man
- Sponsors Ono Pharmaceutical
- 03 Jun 2019 Status changed from recruiting to discontinued.
- 18 Mar 2019 Interim results (n=48) assessing safety, tolerability and pharmacokinetics presented at the 101st Annual Meeting of the Endocrine Society.
- 03 Jan 2019 Planned End Date changed from 25 Jan 2019 to 25 Apr 2019.